Abstract
No translate
No translate
No translate
No translate
Phan Tuấn Đạt; Phạm Mạnh Hùng
References
1.
1. Ay M. O., Erenler A. K., Dogan T., et al. (2017), “Diagnostic value of copeptin in acute myocardial infarction”, EurRevMedPharmacolSci, 21(7), pp.1576-1582.
2.
2. ClericoA.,PassinoC.(2017), “Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction”, Clinicalchemistry, 63(5), pp. 1045-1046.
3.
3. Dagres N., Hindricks G. (2013), “Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death?”, European heart journal, 34(26), pp.1964-1971.
4.
4. Goldberg R. J., McCormick D., Gurwitz J. H., et al. (1998), “Age-related trends in short-and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995)”, The American journal of cardiology, 82(11), pp. 1311-1317.
5.
5. Kelly D., Squire I. B., Khan S. Q., et al. (2008), “C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction”, Journalofcardiacfailure, 14(9), pp.739-745.
6.
6. KhanS.Q.,O’BrienR.J.,StruckJ.,etal.(2006), “C-terminal proVasopressin (Copeptin) as a Novel and Prognostic Marker In Acute Myocardial Infarction-The Leicester Acute Myocardial infarction Peptide (LAMP) Study”, AmHeartAssoc.
7.
7. LattucaB.,SyV.,NguyenL.S.,etal.(2019), “Copeptin as a prognostic biomarker in acute myocardial infarction”, International journal of cardiology, 274, pp.337-341.
8.
8. Lee H., Eisenberg M. J., Schiller N. B. (1995), “Serial assessment of left ventricular function after myocardial infarction”, Americanheartjournal, 130(5), pp.999-1002.
9.
9. MöckelM.,SearleJ.,HammC.,etal.(2015), “Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study”, Europeanheartjournal, 36(6), pp. 369-376.
10.
10. NarayanH.,DhillonO.S.,QuinnP.A.,etal.(2011), “C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study”, ClinicalScience, 121(2), pp. 79-89.
11.
11. NiuJ.M.,MaZ.L.,XieC.,etal.(2014), “Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction”, Genet Mol Res, 13(3), pp.6177-6183.
12.
12. Nordenskjöld A. M., Baron T., Eggers K. M., et al. (2018), “Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease”, International journalofcardiology, 261, pp. 18-23.
13.
13. Radosavljevic R. M., Radovanovic N., Vasiljevic Z., et al. (2016), “Usefulness of NT-proBNP in the follow-up of patients after myocardial infarction”, Journalofmedicalbiochemistry, 35(2), pp.158-165.
14.
14. SohailQ.K.,OnkarS.D.,RussellJ.O.,etal.(2007), “C-terminal proVasopressin (Copeptin) as a Novel and Prognostic Marker In Acute Myocardial Infarction-The Leicester Acute Myocardial infarction Peptide (LAMP) Study”, Circulation, 115, pp.2103-2110.
15.
15. Thygesen K., J. S. Alpert, Jaffe A. S., et al. (2019), “Fourth universal definition of myocardial infarction (2018)”, Europeanheartjournal, 40(3), pp. 237-269.
16.
16. Tsai T. H., Chua S., Hussein H., et al. (2011), “Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention”, Critical care medicine, 39(3), pp. 436-442.
Tác giả
Đỗ Quang Huân: Khoa Nội Tim mạch, Viện Tim TP. Hồ Chí Minh;
Nguyễn Anh Vũ: Bộ môn Nội, Trường Đại học Y Dược, Đại học Huế;
Files
Article Views311
Document Views0
Downloads6
Section
NGHIÊN CỨU LÂM SÀNG
Issue
Số 91+92, 2021
Category
BỆNH MẠCH VÀNH
Pages
152-157
Copyright Holder
2020 Tạp chí Tim mạch học Việt Nam